Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.
Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand; Center of Excellence in Osteoarthritis and Musculoskeleton, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok 10330, Thailand.
Int J Infect Dis. 2023 Sep;134:18-22. doi: 10.1016/j.ijid.2023.05.005. Epub 2023 May 18.
To assess the binding antibody response and strength of neutralization against Omicron BA.5 in serum samples from children with different antigen exposures (infection/vaccination) and hybrid immunity.
This study recruited children aged 5-7 years. All samples were tested for anti-nucleocapsid immunoglobulin (Ig)G, anti-receptor binding domain (RBD) IgG, and total anti-RBD Ig. Neutralizing antibodies (nAbs) against Omicron BA.5 were determined using a focus reduction neutralization test.
A total of 196 serum samples from unvaccinated children with infection (n = 57), vaccination alone (n = 71), and hybrid immunity (n = 68). Our results showed that 90% of the samples from children with hybrid immunity, 62.2% from two-dose vaccination, and 48% from Omicron infection alone had detectable nAbs against Omicron BA.5. The highest neutralizing titer was observed in infection plus two-dose vaccination, which reached 6.3-fold increase, whereas nAb titers in two-dose vaccination was comparable to Omicron-infected sera. However, sera from pre-Omicron infection and single-dose vaccination failed to neutralize Omicron BA.5; although, the total anti-RBD Ig were comparable with Omicron-infected sera.
This result highlights that hybrid immunity provided cross-reactive antibodies to neutralize Omicron BA.5 compared with either vaccination or infection alone. The finding emphasizes the importance of vaccination in unvaccinated children who are infected with pre-Omicron or Omicron variants.
评估具有不同抗原暴露(感染/接种)和混合免疫的儿童血清样本中针对奥密克戎 BA.5 的结合抗体反应和中和抗体强度。
本研究招募了 5-7 岁的儿童。所有样本均检测了核衣壳蛋白 IgG、受体结合域 IgG 和总抗 RBD Ig。使用空斑减少中和试验测定针对奥密克戎 BA.5 的中和抗体(nAb)。
共检测了 196 份来自未接种疫苗且感染(n=57)、仅接种疫苗(n=71)和混合免疫(n=68)儿童的血清样本。结果显示,90%的混合免疫儿童样本、62.2%的两剂疫苗接种儿童样本和 48%的奥密克戎单独感染儿童样本中可检测到针对奥密克戎 BA.5 的 nAb。感染加两剂疫苗接种的中和抗体滴度最高,达到 6.3 倍的增加,而两剂疫苗接种的 nAb 滴度与奥密克戎感染血清相当。然而,来自 pre-Omicron 感染和单剂疫苗接种的血清无法中和奥密克戎 BA.5;尽管总抗 RBD Ig 与奥密克戎感染血清相当。
该结果强调了与单独接种疫苗或感染相比,混合免疫提供了交叉反应性抗体来中和奥密克戎 BA.5。这一发现强调了在未接种疫苗且感染 pre-Omicron 或奥密克戎变异株的儿童中接种疫苗的重要性。